Europe Biopsy Devices Market Report by Product (Needle Based Biopsy Devices, Biopsy Forceps, Localization Wire, and Others Products), Imaging Technology (CT scan, Stereotactic Guided, Ultrasound Guided, MRI Guided, and Others), End-User (Hospital and Clinics, Diagnostics Laboratories, and Other), Country and Company Analysis 2024-2032

Europe Biopsy Devices Market Analysis

Europe Biopsy Devices Market reached US$ 636.4 Million in 2023. It is projected to grow at a CAGR of 5.99% from 2024 to 2032. Renub Research forecasts it to reach US$ 1,074.0 Million by 2032.

Biopsy devices are essential in European healthcare. They extract tissue samples vital for diagnosing illnesses like cancer and play a pivotal role in ensuring correct analysis and effective treatment plans. The demand for those gadgets continues to surge because of rising cancer rates and a developing emphasis on early detection and customized remedies. Technological improvements like minimally invasive biopsy techniques also propel their adoption throughout Europe. This allows healthcare experts to conduct procedures more precisely and decrease patient discomfort.

Europe Biopsy Devices Growth Factors

•    Persistent Health Conditions

Chronic ailments in Europe, including cancer, are ordinary, with over one-third (36.1%) of EU residents reporting long-standing health troubles in 2022 (Eurostat). Early and correct analysis is essential for remedy fulfillment, central to the multiplied demand for biopsy methods to acquire tissue samples. Biopsy devices are vital equipment facilitating sample extraction for evaluation. As healthcare systems address rising diagnostic wishes, demand for biopsy devices grows. This emphasizes their essential position in diagnosing chronic illnesses, particularly cancer, throughout Europe.

•    The Population of Europe is Experiencing Aging

As the population of Europe ages, the prevalence of illnesses requiring biopsies will increase. This is particularly true amongst older adults, who are more vulnerable to fitness issues. The European Commission states that as of 2023, the EU population stood at 448.8 million, with over one-fifth (21.3%) aged sixty-five years and above. The median age of the EU's populace reached 44.5 years by the same date. This demographic transition propels the boom of the Europe biopsy devices market as the demand for those tools escalates to ensure particular analysis and treatment of age-associated illnesses.

•    Transition towards Personalized Treatments

The shift to personalized remedies emphasizes the want for precise diagnoses through tissue biopsies. This fuels the demand for advanced biopsy devices in Europe. Accurate tissue sampling is vital for tailor-made treatments based on patient genetics and clinical needs. For instance, Sorek Medical Systems Ltd. evolved biopsy devices that robotically split tissue samples for chemical fixation and freezing preservation. EU-funded testing targets to validate these devices for medical applications, probably reaping the rewards for cancer prognosis and pharmaceutical development for personalized medicinal drugs. Innovative biopsy technology refines diagnostics, improving patient outcomes and advancing personalized medicinal drug initiatives continent-wide.

•    Government Initiatives are Vigorously advancing Cancer Screening Programs

European governments actively promote cancer screening programs and support studies in clinical technologies. Europe's Beating Cancer Plan prioritizes prevention, early detection, diagnosis, and treatment, enhancing cancer sufferers' and survivors' quality of life. The EU4Health project, a part of this plan, launches SOLACE to enlarge lung cancer screening throughout Europe. This initiative aims to ensure screening accessibility for all social and economic companies. Governments foster a positive environment for growing the Europe biopsy devices market specializing in early cancer detection and treatment. This strategic technique stimulates innovation and funding, driving increased demand for advanced diagnostic tools to combat cancer successfully.

Needle-based biopsy devices might rank as a top product in the Europe Biopsy Devices Market

Needle-based biopsy devices are among the leading products in the Europe biopsy devices market. This is because they effectively obtain tissue samples for accurate analysis. These gadgets offer minimally invasive approaches, decreasing patient discomfort and recuperation time. With the rising demand for precise and efficient biopsy techniques, healthcare professionals and European patients prefer needle-based biopsy devices.

United Kingdom Biopsy Devices Market

The United Kingdom commands a notable part of the Europe biopsy devices market. Research posted in the esteemed cancer journal Annals of Oncology states that in 2023, about 172,314 individuals in the UK are projected to succumb to cancer, contributing to a total of 261,990 cancer-related deaths within the EU (EU-27). The UK's healthcare system is recognized for its robustness, particularly in prioritizing the early detection and treatment of illnesses like cancer. This cognizance underscores the demand for biopsy devices as critical equipment for specific diagnosis in the UK healthcare sector.

The UK also hosts numerous outstanding scientific device producers and research institutions devoted to pioneering revolutionary biopsy technology. These entities are pivotal in driving the increase and advancement of the biopsy device market locally and across Europe. Governmental projects and investment allocations for clinical research further solidify the UK's importance as a critical player in the Europe biopsy device market. This ensures continuous progress and innovation. As part of the NHS Cervical Screening Programme, women aged 25 to 64 are routinely invited for cervical screening. This targets to pick out cervix abnormalities early to prevent the development of cervical cancer if left undetected and untreated.

Europe Biopsy Devices Company News

Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Exact Sciences (Genomic Health), Biocept, Roche Diagnostics, Myriad Genetics Inc., Qiagen, NeoGenomics Laboratories, and Quest Diagnostics Inc. are the essential companies in the Europe biopsy devices market.

• In September 2023 - Mermaid Medical unveiled its latest soft tissue biopsy solutions, featuring the M∙Biopsy® Semi-Automatic and Fully Automatic Biopsy Needles.
• In August 2022 - Mammotome introduced the inaugural Vacuum-Assisted Breast Biopsy System tailored for Lesion Excision.
• In August 2022 - Throughout Europe, Predicine introduced its CE-marked PredicineCARE for genomic profiling in blood and urine. The liquid biopsy assay, targeting 152 genes, is tailored for cancer patients' diagnosis.
• In May 2022 - Guardant Health, Inc. revealed the availability of Europe's initial blood-based cancer testing services at the VHIO liquid biopsy testing facility in Barcelona. These services are founded on Guardant Health's cutting-edge digital sequencing platform

Product – Market breakup in 4 viewpoints:

1.    Needle Based Biopsy Devices
2.    Biopsy Forceps
3.    Localization Wire
4.    Others Products

Imaging Technology – Market breakup in 5 viewpoints:

1.    CT scan
2.    Stereotactic Guided
3.    Ultrasound Guided
4.    MRI Guided 
5.    Others

End-User – Market breakup in 3 viewpoints:

1.    Hospital and Clinics
2.    Diagnostics Laboratories
3.    Other

Country – Market breakup of 5 Countries:

1.    United Kingdom
2.    France
3.    Germany
4.    Italy
5.    Spain
6.    Russia
7.    Rest of Europe

All the Key players have been covered from 3 Viewpoints:

•    Overview
•    Recent Development
•    Revenue Analysis

Company Analysis:

1.    Becton, Dickinson and Company
2.    Thermo Fisher Scientific Inc.
3.    Bio-Rad Laboratories
4.    Exact Sciences (Genomic Health)
5.    Biocept
6.    Roche Diagnostics
7.    Myriad Genetics Inc.
8.    Qiagen
9.    NeoGenomics Laboratories
10.    Quest Diagnostics Inc.

Report Details: